4th Jun 2010 07:00
|
Press Release |
04 June 2010 |
LiDCO Group Plc
("LiDCO" or the "Company")
Directors dealing and grant of options
The Board of LiDCO Group Plc (AIM: LID), the cardiovascular monitoring company, announces that on 3 June 2010, in accordance with the Company's Employee Share Option Schemes, options were granted to two Directors to subscribe for new ordinary shares of 0.5p each ("Ordinary Shares") in the Company as detailed below.
The Company also announces the purchase by Paul Clifford, Finance Director, of 75,000 Ordinary Shares on 3 June 2010 at 20.0 pence each. Subsequent to this share purchase, the Directors' interest in the Company is as shown below:
|
Director |
Number of options |
Exercise Price |
Exercise Period |
Total Number of options held |
Ordinary Shares held |
% of fully diluted ordinary shares |
|
John Barry |
100,000 |
19.92p |
2013 - 2020 |
3,337,017 |
429,642 |
0.21% |
|
Paul Clifford |
100,000 |
19.92p |
2013 - 2020 |
241,000 |
575,000 |
0.29% |
|
|
|
|
|
|
|
|
In addition, options over a further 582,750 new Ordinary Shares have been granted to employees of the Company on the same terms as above.
- ENDS -
For more information please contact:
|
LiDCO Group Plc |
|
|
Terry O'Brien - Chief Executive John Rowland - Company Secretary |
Tel: +44 (0)20 7749 1500 www.lidco.com |
|
FinnCap |
|
|
Geoff Nash / Stephen Norcross / Henrik Persson |
+44 (0)20 7600 1658 www.finncap.com |
Media enquiries
|
Abchurch Communications |
|
|
Heather Salmond / Joanne Shears / Simone Elviss |
+44 (0)20 7398 7728 www.abchurch-group.com |
|
|
About LiDCO Group Plc
LiDCO is a supplier of minimally invasive hemodynamic monitoring equipment and disposables to hospitals. These products are used primarily for the management of adult hospital patients requiring critical care or at major cardiovascular risk. LiDCO's computer-based technology can significantly reduce the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas' Hospital, London. LiDCO is based in the UK and its shares are traded on AIM. For more information please see www.lidco.com.
The Company's sales office is in Cambridge, its manufacturing facility / general administration base is in Hoxton, London, and its current products are:
* LiDCOplus is a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%)
* LiDCOrapid: our new cardiac output monitor designed specifically for use in the Operating Theatre for fluid and drug management. The monitor enables acute-care physicians to get accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being both during and after surgery. The benefits are:
|
·; |
Early and rapid warning of hemodynamic change |
|
·; |
Aids choice of therapeutic route: fluid or drug |
|
·; |
Quantification of hemodynamic response, particularly stroke volume |
|
·; |
Guides more effective delivery of fluids - the right amount at the right time |
|
·; |
Advanced hemodynamic care has been shown to contribute to: - Reduced morbidity and complications, length of stay & overall cost of care |
* LiDCO single-patient-use disposables used in conjunction with the LiDCOplus and LiDCOrapid.
* LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.
LiDCO's Distribution Network:
The Company sells via its own direct sales force to hospitals in the UK, and in export markets predominantly through a worldwide network of speciality critical care and anesthesia distributors.
Related Shares:
LID.L